Background: Nonbacterial prostatitis, together with chronic pelvic pain syndrome, accounts for 90ââ?¬â??95 % of\nprostatitis cases. Anti-inflammatory medications are commonly used to reduce storage/inflammatory symptoms\nthat can deteriorate quality of life. The purpose of this study was to observe the efficacy and safety of\nbeclomethasone dipropionate rectal suppositories (TopsterÃ?®) in inflammations of the lower urinary tract in men.\nMethods: Patients underwent diagnostic and therapeutic protocols according to current evidence-based practice.\nEfficacy assessments: voiding parameters, perineal pain, International Prostate Symptom Score (IPSS), digital rectal\nexamination (DRE). Adverse events and patient compliance were recorded throughout the study.\nResults: One hundred eighty patients were enrolled, mean age 52 Ã?± 14.97. Most frequent diagnosis: nonbacterial\nprostatitis (85 %). All patients completed visits 1 and 2. All patients were treated with beclomethasone dipropionate\n(BDP) suppositories, 136/180 also with Serenoa repens (SR) extract. Antibiotics were rarely required.\n162/180 patients presented clinically significant improvements and terminated treatment.\nMean change vs. baseline in voiding frequency: âË?â??3.55 Ã?± 2.70 n/day in patients taking only BDP and âË?â??3.68 Ã?± 2.81 n/day\nin those taking both BDP and SR (P<.0001 in both groups). Uroflowmetry improved significantly; change from baseline\n3.26 Ã?± 5.35 ml/s in BDP only group and 5.61 Ã?± 7.32 ml/s in BDP + SR group (P = 0.0002 for BDP, P<.0001 for BDP + SR).\nUrine stream normal in 35 % of patients at visit 1 and 57.22 % of patients at visit 2. Mean change in perineal pain, on\n0ââ?¬â??10 VAS, âË?â??0.66 Ã?± 2.24 for BDP only group (P = 0.0699) and âË?â??1.37 Ã?± 2.40 for BDP + SR group (P<.0001). IPSS increased at\nvisit 2. No adverse events were reported.\nFor all parameters, none of the comparisons between groups was found to be statistically significant.\nConclusion: This study confirmed the drugââ?¬â?¢s good safety profile. We also observed an improvement in the main\nstorage symptoms and clinical findings associated with lower urinary tract inflammation in patients treated with\nbeclomethasone dipropionate suppositories.
Loading....